arrow_back Civic Audit
Share share

Increased Transparency in Generic Drug Approvals

New rules aim to make it easier for generic drug companies to get information on whether their product is identical to the original drug. This could speed up the introduction of cheaper alternatives to the market, potentially lowering drug costs for citizens and increasing their availability.
Key points
Companies can ask if a generic drug matches the original, and the agency must respond.
If the generic drug is not identical, the agency will identify the differences.
The agency will not change its decision on sameness unless the original drug was withdrawn for safety reasons or due to an error.
Clear guidelines for assessing generic drug sameness will be developed within one year.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 117_HR_7032
Sponsor: Rep. Kuster, Ann M. [D-NH-2]
Process start date: 2022-03-09